Abbott Laboratories Scores High on P/E/Growth Model

Abbott Laboratories shines with a 91% rating from the P/E/Growth Investor model. With strong fundamentals and reasonable valuation signals, the stock appears to be a favorable option for investors navigating the medical equipment sector.

Date: 01-03-2025

AI Rating: 7

Earnings Per Share (EPS)
The report indicates that Abbott Laboratories passes the EPS growth rate criterion, highlighting strong earnings performance.

Free Cash Flow (FCF)
The free cash flow metric is categorized as neutral. This suggests that while the company is generating cash, it may not stand out compared to peers.

Total Debt/Equity Ratio
Abbott’s total debt/equity ratio passes, indicating a sound financial structure with manageable debt levels.

Sales and P/E Ratio
The sales and P/E ratio also pass, indicating that Abbott is trading at reasonable valuations in relation to its earnings growth.

In summary, the analysis reveals a strong overall performance by Abbott Laboratories, especially in growth metrics related to earnings, which are crucial indicators for investors. However, the neutral stance on free cash flow may warrant a closer evaluation by potential investors.

Stocks: ABT